Participants were included in the Classification in Axial Spondyloarthritis Inception Cohort Study (CLASSIC) if they were referred to a rheumatologist with undiagnosed chronic back pain occurring before 45 years of age, with ≥3 months' duration, and with suspicion of axial spondyloarthritis [2]. Global assessments were conducted to validate the criteria using clinical assessment, laboratory analyses, pelvic radiographs, local MRI, and a centralised review of imaging data. A prespecified sensitivity of ≥75% and specificity of ≥90% was used to select diagnostic criteria. A total of 1,015 participants from 61 centres in 27 countries were included.
Following central review of data, 36.4% of participants in the cohort were diagnosed with axial spondyloarthritis. Several diagnostic models were proposed based on imaging, genetic, and clinical criteria. The model reaching the highest specificity (sensitivity of 79.5% and specificity of 90.4% for local readers) was based on a score ≥11, calculated as the sum of the following:
- MRI indicating axial spondyloarthritis (8) or radiographic sacroiliitis (7)
- HLA-B27 positivity (4)
- Inflammatory back pain (3)
- Peripheral arthritis (1)
- Inflammatory bowel disease (1)
- Acute anterior uveitis (1)
- Heel enthesitis (1)
- Elevated C-reactive protein (1)
- Psoriasis (1)
- Maksymowych WP, et al. Ann Rheum Dis. 2009;68(6):777-83.
- Maksymowych WP, et al. The assessments in Spondyloarthritis International Society (ASAS) and Spondyloarthritis Research and Treatment Network (SPARTAN) revised classification criteria for axial spondyloarthritis: Development and validation in the Classification in Axial SpA Inception Cohort Study. ACR Convergence, 24–29 October 2025, Chicago, IL, USA.
Copyright ©2025 Medicom Medical Publishers
Posted on
Previous Article
« LEVI-04 holds potential to be the first disease-modifying therapy for knee osteoarthritis Next Article
Phase 2b data show that rosnilimab is effective in rheumatoid arthritis »
« LEVI-04 holds potential to be the first disease-modifying therapy for knee osteoarthritis Next Article
Phase 2b data show that rosnilimab is effective in rheumatoid arthritis »
Table of Contents: ACR 2025
Featured articles
Head-to-head trial shows secukinumab superior to ustekinumab in psoriatic arthritis
IDH1/2 mutations linked to inflammatory and rheumatological disorders
A joint ASAS/SPARTAN initiative proposes revised diagnostic criteria for axial spondyloarthritis
Head-to-head trial shows secukinumab superior to ustekinumab in psoriatic arthritis
Phase 3 data reinforce ianalumab activity in Sjögren’s disease
A joint ASAS/SPARTAN initiative proposes revised diagnostic criteria for axial spondyloarthritis
Advances in Inflammatory and Degenerative Rheumatic Diseases
Deucravacitinib holds promise for patients with psoriatic arthritis
Phase 2b data show that rosnilimab is effective in rheumatoid arthritis
A joint ASAS/SPARTAN initiative proposes revised diagnostic criteria for axial spondyloarthritis
LEVI-04 holds potential to be the first disease-modifying therapy for knee osteoarthritis
A urinary tenascin-C biomarker score predicts long-term kidney function in lupus nephritis
GLP-1 receptor agonists may protect against cardiac events in patients with psoriatic arthritis
Two-year treatment with upadacitinib shows high remission in patients with giant cell arteritis
Novel Immunotherapies and Targeted Treatments
Telitacicept reveals positive efficacy data in Chinese patients with Sjögren’s disease
CAR Treg cells show initial efficacy in hard-to-treat rheumatoid arthritis
Phase 3 data reinforce ianalumab activity in Sjögren’s disease
From Mechanistic Insights to Real-World Practice
Head-to-head trial shows secukinumab superior to ustekinumab in psoriatic arthritis
Many high-risk post-menopausal women in the USA remain undertreated for osteoporosis
Hydroxychloroquine blood level monitoring may reduce toxicity risk in lupus
NTR-441 is an emerging treatment option for rheumatological conditions
IDH1/2 mutations linked to inflammatory and rheumatological disorders
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com
